P4 - Poster Session 4
Event Time: | Wednesday May 8, 2019 11:30 am to 6:30 pm |
Topic(s): | Practice, Policy, and Ethics, General Neurology, Aging, Dementia, Cognitive, and Behavioral Neurology, Cerebrovascular Disease and Interventional Neurology, Child Neurology and Developmental Neurology, Epilepsy/Clinical Neurophysiology (EEG), Headache, Infectious Disease, Movement Disorders, MS and CNS Inflammatory Disease, Neuroepidemiology, Neuromuscular and Clinical Neurophysiology (EMG), Research Methodology, Education, and History |
Director(s): | |
Description: | |
Completion Message: | |
CME Credits: | 0 |
Core Competencies: |
Start/End Time | Title | Faculty |
---|---|---|
Currently there are no events in the timeline. |
Speaker | Disclosure |
---|
Movement Disorders ePoster Session | |||
---|---|---|---|
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Substantia Nigra (SN) Hyperechogenicity is a Reliable Biomarker for Disease Progression From Stage I to Stage II in Early Onset Parkinson’s Disease (EOPD) |
Disclosure: Dr. Ravi has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | A Randomized Trial of Telemedicine for Migraine Management |
Disclosure: Dr. Friedman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder Biopharmaceuticals, Allergan, Amgen, Biohaven, electroCore, Eli Lilly, Promius, Revance, Supernus, Teva, Theranica and Zosano. Dr. Friedman has received personal compensation in an editorial capacity for Neurology Reviews. Dr. Friedman has received research support from Allergan, Autonomic Technologies, Inc (company entered into insolvency April 2019), Eli Lilly, Merck, Zosano.
|
Check Point Inhibitors and Paraneoplastic Neurological Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Neurologic Adverse Events associated with Immune Checkpoint Inhibitor Therapy |
Disclosure: Dr. Duong has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Mid-Atlantic Region State Ratios of Emergency Hyperbaric Chambers (EHC) to Comprehensive Stroke Centers (CSC) for Symptomatic Cerebral Air Embolus (SCAE) |
Disclosure: Dr. Taylor has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | A case of aggressive motor neuron disease without profound loss of motor neuron cells |
Disclosure: Dr. Liu has nothing to disclose.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Lack of Standardization of the Level of Encephalopathy on EEG: a Barrier to the Widespread Use of EEG for Brain Monitoring |
Disclosure: Dr. Maciel has nothing to disclose.
|
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Clinical Characteristics of a Large Cohort of US Patients Enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010–2015 |
Disclosure: Dr. Raymond MPH has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Muscle pattern changes in patients with cervical dystonia (CD) receiving botulinum toxin (BTX) |
Disclosure: Dr. Gutflais has nothing to disclose.
|
NeuroHIV and other Retroviruses | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Cognitive Performance and Total and Regional Brain Volumes in Zambian Youth with HIV |
Disclosure: Dr. Dean has nothing to disclose.
|
Aging and Dementia: Clinical Trials | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Baseline Characteristics from a Phase III Trial of Crenezumab in Early (Prodromal-to-Mild) Alzheimer’s Disease (CREAD) |
Disclosure: Dr. Sink has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities as a full time employee of Genentech, Inc.
|
Movement Disorders ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | The Pseudodystonia: Important Pitfalls in the Diagnosis of Dystonia |
Disclosure: Dr. Pan has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Predictors of Non-Adherence with Acute Migraine Medications |
Disclosure: Dr. Lofchie has nothing to disclose.
|
Check Point Inhibitors and Paraneoplastic Neurological Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Pembrolizumab-Associated Paraneoplastic Disorders: A Case Series |
Disclosure: Dr. Gill has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Unusual Cause of Acute Ischemic Stroke: A Case of Cerebral Air Embolism Post Transthoracic Lung Biopsy |
Disclosure: Dr. Fahimi has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Correlation between Slow Vital Capacity Measured in the Home and in the Clinic for Patients with Amyotrophic Lateral Sclerosis |
Disclosure: Dr. Meng has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cytokinetics employee.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | The Sounds of Seizures: Audio-Triggered Detection by Convolutional Neural Network (CNN) |
Disclosure: Dr. Basha has nothing to disclose.
|
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | A comparison of the clinical and genetic features of Amyotrophic Lateral Sclerosis across Latin American and European populations |
Disclosure: Dr. Hardiman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Wave Life Sciences, Cytokinetics, Treeway. Dr. Hardiman has received personal compensation in an editorial capacity for Taylor and Francis .
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Long-term outcomes of late deep brain stimulation in DYT1 dystonia |
Disclosure: Dr. Ooi has nothing to disclose.
|
NeuroHIV and other Retroviruses | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Increased Caloric Intake is Associated with Lower Cognitive Scores in HIV-Positive Women |
Disclosure: Dr. Warrior has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with John Redmond Esq.
|
Movement Disorders ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Disruption of spermatogenesis and infertility in Ataxia with Oculomotor Apraxia Type 2 (AOA2) |
Disclosure: Dr. Fogel has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Rates of Associated Health Conditions in Those with Migraine vs. Non-migraine Controls: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study |
Disclosure: Dr. Buse has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Dawn Buse PhD has received honoraria from Allergan Amgen Biohaven Lilly Teva and Promius. Dr. Buse has received personal compensation in an editorial capacity for editorial board of Current Pain and Headache Reports. Dr. Buse has received research support from Amgen.
|
Check Point Inhibitors and Paraneoplastic Neurological Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Immune checkpoint inhibitor induced anti-GAD limbic encephalitis |
Disclosure: Dr. Chung has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | A Rare Case of Air Embolus During Administration of tPA for Acute Ischemic Stroke |
Disclosure: Dr. Southard has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Survival prediction models in motor neuron disease |
Disclosure: Dr. Spinelli has nothing to disclose.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Long-term Stability of Interictal Spike Trajectories in Pediatric Invasive EEG Recordings |
Disclosure: Dr. Tomlinson has nothing to disclose.
|
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Incidence of Venous Thromboembolic Events Among Amyotrophic Lateral Sclerosis Patients in a US Health Insurance Claims Database |
Disclosure: Dr. Kupelian has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Pilot feasibility study of a semi-automated three-dimensional scoring system for cervical dystonia |
Disclosure: Dr. Oyama has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Medtronic, Boston Scientific, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, FP Pharmaceutical Corporation, and Kyowa Hakko Kirin, and Abbvie.
|
NeuroHIV and other Retroviruses | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Rare Case of Human T-lymphotropic Virus-1 (HTLV-1) with Amyotrophic lateral sclerosis |
Disclosure: Dr. Khosa has nothing to disclose.
|
Aging and Dementia: Clinical Trials | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | GeneMatch: A Novel Recruitment Registry using APOE Genotyping to Accelerate Referrals to Alzheimer’s Prevention Studies |
Disclosure: Dr. Langbaum has received research support from Avid/Eli Lilly, Genentech/Roche, Novartis/Amgen.
|
Movement Disorders ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | A single ascending dose (SAD) study of a D1 receptor positive allosteric modulator (LY3154207) in healthy volunteers |
Disclosure: Dr. Svensson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Svensson holds stock and/or stock options in Eli Lilly and Company.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Undiagnosed Chronic Migraine Is Associated With Higher Economic Burden Compared With Diagnosed Chronic Migraine: Results From a Claims-Based Retrospective Study |
Disclosure: Dr. Marcus has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan.
|
Check Point Inhibitors and Paraneoplastic Neurological Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Characterization of Encephalopathy Associated with Immune Checkpoint Inhibitor Therapy |
Disclosure: Dr. Wei has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | A case of accidental ingestion of Hydrogen Peroxide causing massive cerebral gas embolic strokes |
Disclosure: Dr. Bhattacharyya has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Meta-analysis of Genetic Expression Profiles in Amyotrophic Lateral Sclerosis |
Disclosure: Dr. Frank has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with uniQure, Oscine Therapeutics and Sage Therapeutics. Dr. Frank has received research support from Roche/Genentech and Vaccinex/Huntington Study Group.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | EEG source localization comparing low-density EEG including subtemporal coverage with high density EEG |
Disclosure: Dr. Danoun has nothing to disclose.
|
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Progression of Symptoms in relation to the Site of Onset in Amyotrophic Lateral Sclerosis: new Evidence supporting the Prion-like Hypothesis |
Disclosure: Dr. Chio has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Cytokinetics, Roche. Dr. Chio has received research support from Italfarmaco.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | The Dystonia Coalition Natural History Project: Nine Years of Progress |
Disclosure: Dr. Norris has nothing to disclose.
|
NeuroHIV and other Retroviruses | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Teriflunomide Reduces Spontaneous Lymphoproliferation of Peripheral Blood Mononuclear Cells From Patients With Human T-Lymphotropic Virus (HTLV)-1–Associated Myelopathy/Tropical Spastic Paraparesis |
Disclosure: Dr. Akahata has nothing to disclose.
|
Aging and Dementia: Clinical Trials | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | The Alzheimer Prevention Initiative Generation Program: Evaluation of CNP520 in Preclinical Alzheimer's Disease |
Disclosure: Dr. Borowsky has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis and Teva.
|
Movement Disorders ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Preliminary validation of a novel, comprehensive digital biomarker smartphone application to assess motor symptoms in recently diagnosed Parkinson patients |
Disclosure: Dr. Lipsmeier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd.. Dr. Lipsmeier has received royalty, license fees, or contractual rights payments from F. Hoffmann-La Roche Ltd..
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Poor Acute Treatment Optimization and Frequent Nausea in Episodic Migraine (EM) are Associated with New Onset Chronic Migraine (CM): Results from 2017 Migraine in America Symptoms and Treatment (MAST) Study |
Disclosure: Dr. Schwedt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder, Allergan, Amgen, Avanir, Cipla, Dr. Reddy’s Laboratories, Eli Lilly, Ipsen Bioscience, Novartis, Salvia, Teva, and XoC Pharmaceuticals. Dr. Schwedt has received personal compensation in an editorial capacity for Associate Editor for Headache and Cephalalgia journals. Dr. Schwedt has received compensation for serving on the Board of Directors of Aural Analytics and Nocira. Dr. Schwedt has received research support from Amgen.
|
Check Point Inhibitors and Paraneoplastic Neurological Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Nivolumab-induced myasthenia gravis with myositis in patients with genitourinary cancer |
Disclosure: Dr. Sun has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Cerebral Fat Embolus (CFE): A Rare Cause of Multifocal Infarctions with Potential for Full Recovery |
Disclosure: Dr. Taylor has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Two Cases of Spinal Muscular Atrophy due to Mutations in the VRK1 Gene |
Disclosure: Dr. Sung has nothing to disclose.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Age Norms of EEG during Sleep from 0 to 100 years old |
Disclosure: Dr. Paixao has nothing to disclose.
|
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | An Analysis of Free-text Responses by Individuals Enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry |
Disclosure: Dr. Jordan has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Neural Responses Are Abnormal During Reflexive Blinking in Blepharospasm: An Event-Related fMRI Study |
Disclosure: Dr. Nguyen has nothing to disclose.
|
NeuroHIV and other Retroviruses | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Neurofilament Light Chain Protein Levels in HIV Positive Subjects with Neuropathy |
Disclosure: Dr. Damian has nothing to disclose.
|
Aging and Dementia: Clinical Trials | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | A Multidomain Precision Medicine Intervention in Patients at Risk for Dementia due to Alzheimer’s disease |
Disclosure: Dr. Isaacson has nothing to disclose.
|
Movement Disorders ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | STN LFP and SUA characterization of dyskinesia in PD using microelectrode recordings |
Disclosure: Dr. Jimenez Shahed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with St. Jude Medical/Abbott, Medtronic, Boston Scientific, Teva, Bracket,Nuvelution, Sunovion,. Dr. Jimenez Shahed has received research support from Medtronic, St. Jude Medical/Abbott, Lily, Wilsons Therapeutics, Sunovion, Nuvelution.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine |
Disclosure: Dr. Masters-Israilov has nothing to disclose.
|
Check Point Inhibitors and Paraneoplastic Neurological Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Hunting the real culprit: a complex case of nivolumab-related myelitis. |
Disclosure: Dr. Poretto has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Tip-of-the-Basilar Stroke secondary to Fat Embolization after Hip Arthroplasty |
Disclosure: Dr. Gopal has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Oculomotor Dysfunction in Motor Neuron Disease |
Disclosure: Dr. Lu has nothing to disclose.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | EEG Source Imaging from Standard Long-term Video EEG Recording in Patients with Medically-refractory Focal Epilepsy |
Disclosure: Dr. Cox has nothing to disclose.
|
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | PRO-ACE: Global Collaborative Ecosystem in a Post-PRO-ACT Era |
Disclosure: Dr. Sherman has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Wireless, Wearable, Soft Electronics for Blepharospasm Assessment |
Disclosure: Dr. Scorr has nothing to disclose.
|
NeuroHIV and other Retroviruses | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Inhibiting Mononuclear Phagocyte Functions in a HIV Associated Neurocognitive Disorders Mouse Model |
Disclosure: Dr. Tyor has nothing to disclose.
|
Aging and Dementia: Clinical Trials | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Efficacy of Memantine Added to Cholinesterase Inhibitors on SIB Higher-Order Cognitive Domains: Pooled Post Hoc Analysis of 2 Randomized Controlled Trials in Patients With Moderate to Severe AD |
Disclosure: Dr. Schmitt has received research support from NIH.
|
Movement Disorders ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Gender disparities in deep brain stimulation surgery for Parkinson’s disease |
Disclosure: Dr. Garbin Di Luca has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | 'Sleep Disturbance and Environmental Reactivity as Potential Mechanisms for Comorbidity of Mood and Anxiety Disorders with Migraine |
Disclosure: Dr. Lateef has nothing to disclose.
|
Check Point Inhibitors and Paraneoplastic Neurological Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Pembrolizumab-Induced Myasthenia Gravis |
Disclosure: Dr. ALGaeed has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Erythrocytapheresis: An emerging treatment option for cerebral fat embolism from hemoglobinopathy related bone marrow necrosis. |
Disclosure: Dr. Siddiqui has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Observational Quantitative Data in Adult Patients with SMA Dosed with Nusinersen |
Disclosure: Dr. Burian has nothing to disclose.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Longitudinal Analysis of Interictal EEGs in Patients with TLE and Hippocampal Sclerosis |
Disclosure: Dr. Brito has nothing to disclose.
|
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Forecasting Multiple Sclerosis Hospitalization and Healthcare Burden in the United States from 2017 to 2040 |
Disclosure: Dr. Sharma has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Golfer’s Cramp: Effect of Propranolol and Looking at the Hole |
Disclosure: Dr.Adler has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Acadia Jazz Neurocrine Scion and Sunovion.
|
NeuroHIV and other Retroviruses | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Occurrence of pneumocystis pneumonia in patients with neurological disease on immunosuppression: a single-center investigation |
Disclosure: Dr. Li MD has nothing to disclose.
|
Aging and Dementia: Clinical Trials | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | SIB Maintenance of Response With Memantine Added to Cholinesterase Inhibitors: Pooled Post Hoc Analysis of 2 Randomized Controlled Trials in Patients With Moderate to Severe AD |
Disclosure: Dr. Schmitt has received research support from NIH.
|
Movement Disorders ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Hyperglycemic Induced Chorea-Ballismus Responsive to Valbenazine: a Video Case Report and Review of the Literature. |
Disclosure: Dr. Saunders has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Methylation Analyses of Stress-Modified Genes in Migraine |
Disclosure: Dr. Oterino Duran has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Almirall, Merck Serono, TEVA, Sanofi Genzyme, Allergan, MSD and Novartis. Dr. Oterino Duran has received research support from Sanofi Genzyme, Novartis.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | NFL pattern in progressive Multiple Sclerosis cohort under MD1003 treatment |
Disclosure: Dr. Pignolet has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Delayed Diagnosis of Fibrocartilaginous Embolism: Assessing the Vertebral Body on MRI |
Disclosure: Dr. Isaac has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Feasibility and Validation of Modified Oculobulbar Facial Respiratory Score (mOBFRS) in Amyotrophic Lateral Sclerosis |
Disclosure: Dr. Goyal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acceleron, Alexion, CSL Behring, and MT Pharma.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Quantitative EEG of Intracranial Recordings for Detection of Seizure Onset and Localization Compared to Standard Intracranial Tracing |
Disclosure: Dr. Gangloff has nothing to disclose.
|
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Effects of cigarette smoking and smoking cessation on Multiple Sclerosis severity: a cross-sectional study |
Disclosure: Dr. Ivashynka has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Hand Motor Control in Patients with Cervical Dystonia: an fMRI Study |
Disclosure: Dr. Hok has nothing to disclose.
|
NeuroHIV and other Retroviruses | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Minimal Effect on Cognitive Function Despite High Prevalence of Mental Health Disorders in Treated HIV |
Disclosure: Dr. Horne has nothing to disclose.
|
Aging and Dementia: Clinical Trials | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Sildenafil Alters Hippocampal Fractional Amplitude of Low Frequency Fluctuations (fALFF) in Patients with Alzheimer’s Disease |
Disclosure: Dr. Samudra has nothing to disclose.
|
Movement Disorders ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Gait Analysis of GBA Mutation Carriers with Parkinson’s Disease |
Disclosure: Dr. Gera has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Healthcare Expenditure in Migraine Compared to Other Leading Causes of Disability: Adequate or Not? |
Disclosure: Dr. Schaetz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Pharma AG, Switzerland.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Longitudinal stability of anti–JC virus (JCV) antibody index over 2 years in multiple sclerosis (MS) patients treated with natalizumab in the ASCEND study |
Disclosure: Dr Mason is an employee of Biogen and receives personal compensation for employment. Dr Mason is an employee of Biogen and has received stock options from Biogen. Dr Mason is an employee and held stock in Biogen.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | CNS Manifestations of Hemophagocytic Lymphohistiocytosis (HLH) |
Disclosure: Dr. Edwards has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Monitoring and promoting effectiveness and adherence to non-invasive ventilation in motor neurone disease using EncoreAnywhere telemonitoring: a pilot and feasibility, randomised controlled trial. |
Disclosure: Dr. James has nothing to disclose.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Validation of a dry-electrode EEG recording system: Results of a multi-reader blinded comparison to standard EEG |
Disclosure: Dr. Zarroli has nothing to disclose.
|
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | An increase in the prevalence of Multiple Sclerosis has moved Kuwait to a high-risk zone |
Disclosure: Dr. Alroughani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Biologix, Merck, Novartis, Roche and Sanofi. Dr. Alroughani has received research support from Biogen, Merck, Novartis, Roche and Sanofi.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Cervical dystonia patient’s satisfaction level after 3 years of botulinum toxin treatment |
Disclosure: Dr. Misra has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen Pharma.
|
NeuroHIV and other Retroviruses | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Inflammatory HIV-associated progressive multifocal leukoencephalopathy associated with high CD4 count |
Disclosure: Dr. Ding has nothing to disclose.
|
Aging and Dementia: Clinical Trials | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Metformin and Newer Oral Hypoglycemic Agents are Associated with Better Cognitive Test Performance Over Ten Years in Older Diabetic Men |
Disclosure: Dr. Duarte has nothing to disclose.
|
Movement Disorders ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Changes to Levodopa Daily Dose in Parkinson’s Disease (PD) Patients with Dyskinesia While on GocovriTM (Amantadine) Extended Release Capsules: a Two-Year Phase 3 Open Label Study Analysis |
Disclosure: Dr. Isaacson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Acadia, Acorda, Adamas, Addex, Allergan, Amarantus, Avid, Axovant, AZTherapies, Biogen, Britannia, Eisai, Eli Lilly, Enterin, GE Healthcare, Impax, Intec Pharma, Ipsen, Kyowa, Lundbeck, Michael J. Fox Foundation, Neurocrine, NeuroDerm, NINDS/NIH, Parkinson Study Group, Pfizer, Pharma Two B, Roche, Sanofi, Sunovion, Teva, UCB, US WorldMeds, and Zambon. Dr. Isaacson has received research support from Abbvie, Acadia, Acorda, Adamas, Amarantus, Axovant, AZ Therapies, Benevolent, Biogen, Cavion, Eli Lilly, Enterin, Impax, Intec Pharma, Jazz, Ipsen, Kyowa, Lundbeck, Michael J. Fox Foundation, Neuroderm, Parkinson Study Group, Pfizer, Pharma2B, Roche, Sanofi, Sunovion, Teva, UCB, US WorldMeds.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Message Framing to Determine Best Methods for Discussing Migraine Behavioral Treatments with Persons with Migraine. |
Disclosure: Dr. Jalloh has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Two Cases of Meningitis Associated with Ocrelizumab Therapy |
Disclosure: Dr. Theriault has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Secondary Polycythemia as an Uncommon Cause of Large Vessel Occlusion Resulting in Acute Ischemic Stroke |
Disclosure: Dr. Mulpur has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Accelerated Pathology in Chlorovirus (ATCV-1) Infected SOD1G93A Transgenic ALS Mice and Association of Increased Serum Anti-ATCV-1 IgG1 Subclass with ALS |
Disclosure: Dr. Pattee has nothing to disclose.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Surface-Electromyography (sEMG) Patterns of Clonic Bursts during Generalized Tonic-Clonic (GTC) Seizures |
Disclosure: Dr. Cardenas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Brain Sentinel.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Basal Ganglia and Cerebellar Circuits Have Distinct Roles in Blepharospasm |
Disclosure: Dr. Glickman has nothing to disclose.
|
NeuroHIV and other Retroviruses | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Thrombotic thrombocytopenic purpura (TTP) presenting with severe neurological manifestations in a patient with well-controlled HIV-1 |
Disclosure: Dr. Kimbrough has nothing to disclose.
|
Aging and Dementia: Clinical Trials | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Long-Term Efficacy for Parkinsonism and Safety of Zonisamide in Patients with Dementia with Lewy Bodies: A Phase III Trial |
Disclosure: Dr. Toya has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sumitomo Dainippon Pharma Co., Ltd.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | A Randomized Controlled Trial to Assess the Effect of Telephone Based Motivational Interviewing on the Initiation and Adherence to Behavioral Therapy for Migraine |
Disclosure: Dr. Minen has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Fingolimod related cryptococcal meningitis and immune reconstitution inflammatory syndrome in two patients with multiple sclerosis |
Disclosure: Dr. Cuascut Lassus has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Multiterritorial ischemic strokes in idiopathic hypereosinophilic syndrome |
Disclosure: Dr. Lee has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Brain White Matter MRI Differentiates Kennedy’s Disease from Other Motor Neuron Disease Clinical Phenotypes |
Disclosure: Dr. Spinelli has nothing to disclose.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | In the kingdom of triphasic waves, white matter is the eminence grise |
Disclosure: Dr. Kotchetkov has nothing to disclose.
|
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Lewy body dementia (LBD) prevalence and cholinesterase inhibitor use in Florida |
Disclosure: Dr. Patel has nothing to disclose.
|
NeuroHIV and other Retroviruses | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Immune Reconstitution Inflammatory Syndrome in a newly diagnosed patient with HIV and Central Nervous System Tuberculosis (TB) |
Disclosure: Dr. Abu-hadid has nothing to disclose.
|
Aging and Dementia: Clinical Trials | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Long-term Efficacy of Zonisamide on Parkinsonism in Dementia with Lewy Bodies: A Post-hoc Analysis of Phase 3 Trial |
Disclosure: Dr. Takai has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sumitomo Dainippon Pharma Co., Ltd.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Exploring Natural Cohorts of Chronic Migraine Phenotype |
Disclosure: Dr. Woldeamanuel has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Leprosy in two patients with Relapsing Remitting Multiple Sclerosis (RRMS) treated with Fingolimod |
Disclosure: Dr. Balasa has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Acute Ischemic Stroke in Cancer Patients. A Case-Control Study |
Disclosure: Dr. Pappolla has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Nusinersen for spinal muscular atrophy - results of an expanded access programme |
Disclosure: Dr. Mazurkiewicz Beldzin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Biomarin.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Diagnostic Utility of Continuous sEMG Monitoring in a Home Setting - Real-world use of the SPEAC® System |
Disclosure: Dr. Whitmire has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Brain Sentinel.
|
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Vision loss in Parkinson’s disease: prevalence and association with outcomes among Medicare beneficiaries |
Disclosure: Dr. Hamedani has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Immunogenicity of DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia from a Phase 2 Dose-Escalation Multicenter Study |
Disclosure: Dr. Brashear has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen and Revance. Dr. Brashear has received research support from Wake Forest.
|
NeuroHIV and other Retroviruses | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | PML presenting as an isolated vertigo: a diagnositic challange |
Disclosure: Dr. Moustafa has nothing to disclose.
|
Aging and Dementia: Clinical Trials | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Transcranial Direct Current Stimulation Improves Verbal Fluency in Patients with Primary Progressive Aphasia |
Disclosure: Dr. Hosseini has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Risk of Worse Short-term Outcomes Associated with hospitalization for migraine and co-morbid psychiatric illness: A Nationwide Population-Based Cohort Study |
Disclosure: Dr. Savani has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Dimethyl Fumarate Dose Reduction in Lymphopenic Relapsing Remitting Multiple Sclerosis Patients: Clinical and MRI Outcomes |
Disclosure: Dr. Wong has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Prudent testing of factor V Leiden in Ischemic stroke |
Disclosure: Dr. Kovi has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Fat mass loss correlates with survival in amyotrophic lateral sclerosis patients: prospective cohort study |
Disclosure: Dr. Lee has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Is There a Role for Magnetoencephalography in Pre-surgical RNS Implantation in Drug-Resistant Temporal Lobe Epilepsy? |
Disclosure: Dr. Alshammaa has nothing to disclose.
|
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Risk of readmission for injury in patients with epilepsy in the US |
Disclosure: Dr. Goldstein has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Implementation of the current dystonia classification from 2013 to 2017 |
Disclosure: Dr. Albanese has nothing to disclose.
|
NeuroHIV and other Retroviruses | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | An Unusual Case of Multiple-Ring-Enhancing Lesions on Brain MRI in Varicella Zoster Virus Encephalitis |
Disclosure: Dr. Hasan has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Hepatitis E virus infection and posterior reversible encephalopathy syndrome: a case report and review of the literature. |
Disclosure: Dr. Loggini has nothing to disclose.
|
Aging and Dementia: Clinical Trials | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Safety and Efficacy of Medical Cannabis in Elderly Patients: A Retrospective Review in a Neurological Outpatient Setting. |
Disclosure: Dr. Bargnes has received research support from Dent Family Foundation.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Angiotensin Receptor Blockers and ACE Inhibitors for Migraine Prophylaxis - A Systematic Review |
Disclosure: Dr. Dorosh has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Infectious Risk Stratification in Multiple Sclerosis Patients Receiving Immunotherapy – An Update |
Disclosure: Dr. Graf has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | An Uncommon Cause of Multifocal Intracerebral Hemorrhages: Adult-Onset Leukoencephalopathy with Calcifications and Cysts |
Disclosure: Dr. Pyatka has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Validation of a staging system in ALS: Comparison of the US and European Populations |
Disclosure: Dr. Kwan has nothing to disclose.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Glossokinetic Potentials: Insights from intracranial EEG |
Disclosure: Dr. Kacar Bayram has nothing to disclose.
|
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Characteristics of periventricular nodules in patients with 22q11. 2 deletion syndrome |
Disclosure: Dr. Rezazadeh has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | A dopa-responsive dystonia-Parkinsonism-cerebellar syndrome associated with GCH1 gene mutation. |
Disclosure: Dr. Garrett has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Abulia: A case of Powassan Encephalitis |
Disclosure: Dr. Yalcin has nothing to disclose.
|
Aging and Dementia: Clinical Trials | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Intranasal Glulisine in Down Syndrome: A Pilot Safety and Tolerability Trial |
Disclosure: Dr. Rosenbloom has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Paul Weiss. Dr. Rosenbloom has received research support from Merck Foundation.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Effect of Galcanezumab on Severity of Headache and Associated Symptoms of Migraine in Phase 3 Trials in Patients with Episodic or Chronic Migraine |
Disclosure: Dr. Day has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Evaluating the Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Infusion Related Reactions in Relapsing Forms of Multiple Sclerosis |
Disclosure: Dr. Alvarez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with consulting fees from Actelion, Bayer, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Novartis, and TG Therapeutics. Dr. Alvarez has received research support from Biogen, Genentech, Novartis, TG Therapeutics, and Rocky Mountain MS Center.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Lacunar Strokes in Cryptococcal Meningitis: Clinical and Radiographic Features in a U.S. Cohort |
Disclosure: Dr. Vela-Duarte has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Nusinersen in Adults with Spinal Muscular Atrophy, A Single Center Experience |
Disclosure: Dr. Moshe-Lilie has nothing to disclose.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Ictal urinary urgency localized by Stereo-electroencephalogram. |
Disclosure: Dr. Murray-Frank has nothing to disclose.
|
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Cognitive decline after a mild or moderate stroke and TIA: evidence from the SWIFT Trial |
Disclosure: Dr. Boden-Albala has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Assessment of standing balance by force plate posturography in X-linked Dystonia Parkinsonism (XDP) |
Disclosure: Dr. Stephen has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | West Nile encephalitis in a patient with initially negative CSF serology. |
Disclosure: Dr. Sanmartin has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Migraine and Cluster Headache Classification Using a Supervised Machine Learning Approach: A Multimodal MRI Study |
Disclosure: Dr. Messina has nothing to disclose.
|
Aging and Dementia: Neuropsychology and Clinical Studies II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Structured delirium care pathway is associated with reductions in length of stay, cost and readmissions in hospitalized adults |
Disclosure: Dr. LaHue has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | A Rare Complication of Fingolimod: Case Report of Posterior Reversible Encephalopathy Syndrome |
Disclosure: Dr. Downey Allison has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Hypertension Increases Risk of Ischemic Stroke in Multiple Sclerosis: Retrospective Analysis of a National Database |
Disclosure: Dr. Ikram has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Spinal Muscular Atrophy: A Review of Epidemiology, Burden and Unmet Needs |
Disclosure: Dr. Callan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Ireland Ltd.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | The Prognostic Value of Quantitative EEG in Patients Undergoing Mechanical Thrombectomy for Acute Ischemic Stroke |
Disclosure: Dr. Dickey has nothing to disclose.
|
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Seasonal Variation in Stroke Incidence in Black versus White Medicare Beneficiaries |
Disclosure: Dr. Baig has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Botulinum toxin injection changes resting state cerebellar connectivity in cervical dystonia. |
Disclosure: Dr. Nevrly has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with consultant for Medtronic.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | A Bird Whisperer’s Tale: The unique occurrence of stroke as a precursor to diagnosing West Nile Meningoencephalitis. |
Disclosure: Dr. Jacob has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Acute Anti-Migraine Prescription Varies According to Baseline Cardiovascular Risk and Clinical Characteristics: A Real-World Evidence Study |
Disclosure: Dr. Li has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Li holds stock and/or stock options in Eli Lilly and Company.
|
Aging and Dementia: Neuropsychology and Clinical Studies II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Snow laughing matter: Delirium severity increases in winter months compared with summer months |
Disclosure: Dr. Douglas has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Among Real-world Multiple Sclerosis Patients That Experience Delayed-release Dimethyl Fumarate-associated Lymphopenia, Meaningful Lymphocyte Reconstitution Occurs Approximately 3 Months After Discontinuation of Delayed-release Dimethyl Fumarate |
Disclosure: Dr. Rose has received research support from National Multiple Sclerosis Society, Guthy Jackson Foundation, NIH, Friends of MS, Western Institute for Biomedical Research, and Biogen.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Fabry disease and Stroke: Effectiveness of Enzyme Replacement Therapy (ERT) in Stroke Prevention, a Review with Meta-Analysis |
Disclosure: Dr. Sheng has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Determinants of Mortality Among Hospitalized Patients with Amyotrophic Lateral Sclerosis – Results from the 2016 National Inpatient Sample |
Disclosure: Dr. L'Italien has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharmaceuticals. Dr. L'Italien holds stock and/or stock options in Biohaven Pharmaceuticals which sponsored research in which Dr. L'Italien was involved as an investigator. Dr. L'Italien holds stock and/or stock options in Biohaven Pharmaceuticals. Dr. L'Italien has received research support from Biohaven Pharmaceuticals.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Wearable Sensors for the Detection of Convulsive Seizures |
Disclosure: Dr. McGinn has nothing to disclose.
|
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Disparities, Predictors and Trends of Left Atrial Appendage Closure Among Hospitalized Patients with Atrial Fibrillation in the United States |
Disclosure: Dr. Badi has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Jaw Opening Oromandibular Dystonia following Acute Stroke: Analysis and Review |
Disclosure: Dr. Singhvi has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Case Series: Congenital Zika Virus Infection associated with Epileptic Spasms |
Disclosure: Dr. Diaz Diaz has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Work Activities Associated with Migraine: Results from Migraine in America Symptoms and Treatment (MAST) Study |
Disclosure: Dr. Alam has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Reddy’s Laboratories group of companies.
|
Aging and Dementia: Neuropsychology and Clinical Studies II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Identifying Common Themes in ICU Deaths of Patients with a Diagnosis of Alzheimer Disease |
Disclosure: Dr. Grant has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | No significant risk of malignant melanoma growth under cladribine treatment: in vitro studies |
Disclosure: Dr. Berestjuk has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Sickle Cell Trait and Risk for Early-Onset Ischemic Stroke |
Disclosure: Dr. Zhang has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Analysis of nutritional status as a predictor of survival in patients with bulbar amyotrophic lateral sclerosis (ALS) |
Disclosure: Dr. Bettini has nothing to disclose.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | The Use of Collodion versus Traditional Paste for Reducing Artifact in Ambulatory Electroencephalography Studies in the Pediatric Population |
Disclosure: Dr. Brigham has nothing to disclose.
|
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Comparing the Outcomes of Patients with Idiopathic Subarachnoid Hemorrhage by Three Distinct Perimesencephalic Bleed Patterns |
Disclosure: Dr. Wagner has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | ATP1A3 Gene Mutations Associated with Rapid-Onset Dystonia-Parkinsonism (RDP) Presenting with Functional Neurologic Disorder: A Report of Two Cases |
Disclosure: Dr. Biller has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | The Diagnosis of Pseudorabies Virus Encephalitis and Endophthalmitis by Next Generation Sequencing in Two Chinese Pork Retailers |
Disclosure: Dr. Liu has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Triptan Use and Discontinuation in a Representative Sample of Persons With Migraine: Results From Migraine in America Symptoms and Treatment (MAST) Study |
Disclosure: Dr. Alam has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Reddy’s Laboratories group of companies.
|
Aging and Dementia: Neuropsychology and Clinical Studies II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Caregiver Depression and Emergency Department Utilization in Dementia |
Disclosure: Dr. Guterman has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Serious Adverse Events in Rituximab-Treated Patients with Multiple Sclerosis and Related Disorders |
Disclosure: Dr. Wallach has received research support from Biogen.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Degos' disease: the hint is in the skin |
Disclosure: Dr. Calame has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Dextromethorphan-Quinidine (Nuedexta) Improves Swallowing in Bulbar Onset ALS Patients with Pseudobulbar Affect - Pre-Post Observational Study in 86 ALS Patients |
Disclosure: Dr. Shah has nothing to disclose.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | An Effective Tool for Teaching EEG Interpretation to Residents and Medical Students |
Disclosure: Dr. Hubert has nothing to disclose.
|
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Time Trends, Race Disparities, and Administration of Intravenous Thrombolysis for Acute Ischemic Stroke: A Statewide Study |
Disclosure: Dr. Marszalek has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Pilot trial of botulinum toxin and occupational therapy for Writer’s Cramp |
Disclosure: Dr. Park has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | An unusual case of feline-transmitted Rabies: A Diagnostic and Preventative Approach. |
Disclosure: Dr. Escobar-Montealegre has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Prophylactic Use of SNRIs to Treat Pediatric Migraine via Reduction of Comorbid Anxiety and Depression |
Disclosure: Dr. McAlister has nothing to disclose.
|
Aging and Dementia: Neuropsychology and Clinical Studies II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | The Lived Experience of Lay Caregivers Caring for Persons with Dementia |
Disclosure: Dr. Mayo has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Central Nervous System T Cell Lymphoproliferative Disease Following Treatment with Alemtuzumab |
Disclosure: Dr. Horton has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Diagnostic Challenges in Vascular Myelopathies |
Disclosure: Dr. Passeri has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Structural and Functional Organization of the Brain Connectome in Patients with Different Motor Neuron Diseases: A Multicenter Study |
Disclosure: Dr. Agosta has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Case Report: Change in Electrocorticogram Detection of RNS with Initiation of Ketogenic Diet |
Disclosure: Dr. Greenwood has nothing to disclose.
|
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | For Men Only, High Hematocrit Values Are Associated With Stroke In The Young |
Disclosure: Dr. Bartt has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Identifying Reliable Measures of Impairment in Focal Hand Dystonia Patients |
Disclosure: Dr. Bukhari-Parlakturk has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | An Uncommon Case of Treatment-Responsive SSPE |
Disclosure: Dr. Hocquard has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene?Related Peptide Receptor |
Disclosure: Dr. Moore has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck & Co., Inc. Dr. Moore holds stock and/or stock options in Merck & Co., Inc which sponsored research in which Dr. Moore was involved as an investigator.
|
Aging and Dementia: Neuropsychology and Clinical Studies II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Real World Treatment of Parkinson’s Disease Dementia (PDD) in the United States (U.S.) |
Disclosure: Dr. Schroeder has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Schroeder holds stock and/or stock options in Eli Lilly and Company which sponsored research in which Dr. Schroeder was involved as an investigator. .
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Risk factors for Development of Lymphopenia in Dimethyl Fumarate-treated Patients with Multiple Sclerosis |
Disclosure: Dr. Bloch has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Isolated Cervical Anterior Spinal Artery Aneurysms (CASAAs): A Case Series and The Comprehensive Outcome Analysis of surgical vs non-surgical interventions |
Disclosure: Dr. SirDeshpande has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | CX3CL1 Disruption Differentially Influences the Neuroprotective Effects of Mesenchymal Stromal Cells on ALS |
Disclosure: Dr. Huang has nothing to disclose.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Correlation of Indicators of P300 Cognitive Potentials with Epilepsy Forms |
Disclosure: Dr. Salokhiddinov has nothing to disclose.
|
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Systematic Characterization of Large Vessel Occlusion Strokes at a CSC |
Disclosure: Dr. Desai has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Indications, Outcomes and Cost of pediatric Deep Brain Stimulation Surgeries in the United States: An Analysis of the Kids’ Inpatient Sample |
Disclosure: Dr. Akano has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | West Nile Virus Neuroinvasive Disease Associated with Rituximab Therapy |
Disclosure: Dr. Owens has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Response to Lasmiditan for Acute Treatment of Migraine Based on Prior Response to Triptan Therapy |
Disclosure: Dr. Knievel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulting for Amgen, Lilly, Allergan, Biohaven. Speaking Amgen and Allergan.. Dr. Knievel has received research support from Allergan; Alder.
|
Aging and Dementia: Neuropsychology and Clinical Studies II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | MCI and OSA |
Disclosure: Dr. Patel has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Severe skin reactions associated with Cladribine treatment in patients with multiple sclerosis |
Disclosure: Dr. Mateo-Casas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB Pharma, Sanofi-Genzyme.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Intravascular Lymphoma Presenting with Spinal Cord Infarct and Recurrent Ischemic Strokes |
Disclosure: Dr. Lyden has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Adherence to Riluzole Therapy Improves Time to and Frequency of All Cause Hospitalization in ALS Patients: A Claims-Based Longitudinal Comparative Effectiveness Analysis. |
Disclosure: Dr. L'Italien has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharmaceuticals. Dr. L'Italien holds stock and/or stock options in Biohaven Pharmaceuticals which sponsored research in which Dr. L'Italien was involved as an investigator. Dr. L'Italien holds stock and/or stock options in Biohaven Pharmaceuticals. Dr. L'Italien has received research support from Biohaven Pharmaceuticals.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Assessing Retinal Cytoarchitecture between Temporal Onset Focal and Primary Generalized Seizure Types Utilizing Optical Coherence Tomography |
Disclosure: Dr. Lichtman-Mikol has nothing to disclose.
|
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Is Altitude Associated With Ischemic Stroke In The Young? |
Disclosure: Dr. Salottolo has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Kufor-Rakeb Syndrome with Prominent Dystonia and New Mutations in ATP13A2 Gene in Two Siblings |
Disclosure: Dr. Yamasaki has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | A Quality Improvement Project Studying the Integration of a Proposed Diagnostic Algorithm on Inpatient Encephalitis into the Electronic Medical Record and its Impact on Length of Hospital Stay |
Disclosure: Dr. Kaplan has nothing to disclose.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Impact of OnabotulinumtoxinA on Quality of Life, Health Resource Utilization, and Work Productivity in People With Chronic Migraine: Interim Results From a Prospective, Observational Study (PREDICT) |
Disclosure: Dr. Boudreau has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen, Lilly, and Teva. Dr. Boudreau has received research support from Allergan, Amgen, Lilly, and Teva.
|
Aging and Dementia: Neuropsychology and Clinical Studies II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Vascular dementia in elderly .Population-based study in Matanzas. |
Disclosure: Dr. Munoz Perez has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Delayed-release Dimethyl Fumarate-associated Lymphopenia: On-treatment and Post-treatment Implications |
Disclosure: Dr. Chan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Genzyme, Merck, Novartis, Roche, Teva, Swiss National Fonds, Genzyme and UCB, Clinical and translational neuroscience and the Journal of International medical research. Dr. Chan has received research support from Bayer, Biogen, Genzyme, Merck, Novartis, Roche, Teva, Swiss National Fonds, Genzyme and UCB, Clinical and translational neuroscience and the Journal of International medical research.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Simultaneous Epidural and Intramedullary Hemorrhage: A Case Report. |
Disclosure: Dr. Shah has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Diffusion Tension Imaging as the Biomarker for Amyotrophic Lateral Sclerosis |
Disclosure: Dr. Baek has nothing to disclose.
|
Epilepsy: EEG and Neurophysiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Normalized transfer entropy used as an informational transfer measure of ictal pathophysiology in patients undergoing stereo-EEG for epilepsy surgery |
Disclosure: Dr. Lee has received research support from America Epilepsy Society.
|
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Acute neurological complications after adult single and double lung transplant |
Disclosure: Dr. Rauf has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | The Trend in Botulinum Toxin Injection among Medicare Neurology Providers in the United States from 2012 to 2016 |
Disclosure: Dr. Miri has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | A simple bioinformatics approach to disentangle the etiology and prognosis of CNS infections |
Disclosure: Dr. Tan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Merck, UCB, Sanofi Genzyme and Eisai.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Eptinezumab Increases Days Free from Canonical Migraine-Associated Symptoms Within 1 Month of Treatment in Patients with Chronic Migraine |
Disclosure: Dr. Schim has received personal compensation from the following companies: Consultant: Acorda, Alder, Allergan, Amgen, Avanir, Depomed, electroCore, Lilly, Novartis, Pernix, Promius, Supernus, Teva, Upsher-Smith Grant/research support: Alder, Allergan, Amgen, electroCore, Lilly, Teva Speaker: Acorda, Allergan, Amgen, Avanir, Depomed, electroCore, Lilly, Novartis, Pernix, Promius, Supernus, Teva, Upsher-Smith Grant/research support: Alder, Allergan, Amgen, electroCore, Lilly, Teva
|
Aging and Dementia: Neuropsychology and Clinical Studies II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Characteristics of Young-onset and Late-onset Dementia Patients at a Rural and Remote Memory Clinic |
Disclosure: Dr. Wong has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Immunization and Multiple Sclerosis: Recommendations from the French Multiple Sclerosis Society |
Disclosure: Dr. Lebrun Frenay has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi, Genzyme, Merck, Novartis, Biogen.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Spinal Claudication Due to Anterior Disco-osteo-arterial Conflict Mimicking Stiff Person Syndrome |
Disclosure: Dr. Murphy has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Diminshed Muscle Oxygenation During Exercise in Ambulatory Spinal Muscular Atrophy Patients |
Disclosure: Dr. Montes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Astellas, Biogen, Cytokinetics, Roche, and Scholar Rock. Dr. Montes has received research support from MDA and NICHD / NIH.
|
Epilepsy: General Medical Issues, PNES, and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | The Relationship between Seizures, Ictal-Interictal EEG Activity, Clinical Outcome, and Dynamic Neurologic Changes following Traumatic Brain Injury |
Disclosure: Dr. Edhi has nothing to disclose.
|
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Association between neurological syndromes and Arbovirus in Buenos Aires - Relationship between Guillain Barre Syndrome, Encephalitis and Myelitis with Zika, Dengue and Chikungunya |
Disclosure: Dr. Kohler has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | RimabotulinumtoxinB (MYOBLOC) in the treatment of adult sialorrhea |
Disclosure: Dr. Ondo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCBPharma, TEVA, USWorldMeds, Neurocrine, and ADAMAS. Dr. Ondo has received research support from Lundbeck, Sunovian, and Neuroderm.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Evaluation of BioFire Film Array Meningitis/ Encephalitis (ME) panel in testing of CSF specimen of patients of meningoencephalitis in Indian scenario |
Disclosure: Dr. Rohatgi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbott, Boehringer, Intas Pharma, Pfizer, Eisai, Genzyme, Sanofi, UCB, Cipla.
|
Migraine II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Does the presence of Cranial Autonomic Symptoms in Chronic Migraine Patients Predict Efficacy of Botox Injections? |
Disclosure: Dr. Riggins has nothing to disclose.
|
Aging and Dementia: Neuropsychology and Clinical Studies II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Subjective Cognitive Impairment: A Clinical and neuropsychological Entity, sustained by a specific Topography of Lesions. The Cingulum Cohort of Marseille, France. |
Disclosure: Dr. Sambuchi has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis |
Disclosure: Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Annexon, Symbiotix, Bionure and Neurona; he has also received travel reimbursement from F. Hoffmann-La Roche Ltd and Novartis for CD20-related meetings and presentation.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Spinal Cord Infarction: A Diagnostic Challenge |
Disclosure: Dr. Passeri has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Population Based Surveillance and Survival Characteristics of Amyotrophic Lateral Sclerosis (ALS) Cases in the Atlanta Metropolitan Area, 2009 – 2011 |
Disclosure: Dr. Punjani MPH has nothing to disclose.
|
Epilepsy: General Medical Issues, PNES, and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Seizures after Cardiovascular Surgery: An unexpected complication |
Disclosure: Dr. Bolaño Diaz has nothing to disclose.
|
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Long-Term Outcomes of Guillain-Barre Syndrome Associated with Zika Virus Infection |
Disclosure: Dr. Walteros has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Patient and Clinician Satisfaction in the ASPIRE Study |
Disclosure: Dr. Francisco has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Merz, and Ipsen. Dr. Francisco has received research support from Allergan, Merz, and Ipsen.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Progressive Multifocal Leukoencephalopathy in an Immunocompetent Patient: A Rare Case with Radiologic-Pathologic Correlation |
Disclosure: Dr. Fecto has nothing to disclose.
|
Aging and Dementia: Neuropsychology and Clinical Studies II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | The Free and Cued Selective Reminding Test Predicts Alzheimer’s Disease Neuropathology |
Disclosure: Dr. Grober has received royalty, license fees, or contractual rights payments from Albert Einstein College of Medicine.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Influence of Clinical and Cerebrospinal Fluid Parameters on the Effect of Therapeutic Plasma Exchange in Patients with Multiple Sclerosis |
Disclosure: Dr. Eienbröker has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | CADASIL in a Patient with Bilateral Internal Carotid Artery Agenesis |
Disclosure: Dr. MacDonald has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Factors Associated with Poor Compliance of Non-invasive Ventilator Support in Patients with ALS |
Disclosure: Dr. Kohli has nothing to disclose.
|
Epilepsy: General Medical Issues, PNES, and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Prognosis and Clinical Factors to Predict Seizure Recurrence in Patients with Alcohol-Related Seizures |
Disclosure: Dr. Chun has nothing to disclose.
|
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | The Pattern of Neurologic Disease in Tanzanian Tribal Populations |
Disclosure: Dr. Aamodt has nothing to disclose.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Individualized OnabotulinumtoxinA Treatment for Lower Limb Spasticity Resulted in High Patient and Clinician Satisfaction in the ASPIRE Study |
Disclosure: Dr. Esquenazi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Ipsen, and Mertz. Dr. Esquenazi has received research support from Allergan and Ipsen.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | A Case of Hepatitis E Transverse Myelitis |
Disclosure: Dr. Doyle has nothing to disclose.
|
Aging and Dementia: Neuropsychology and Clinical Studies II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Color Vision Impairment in Prodromal and Dementia Stages of Lewy Body Disease versus Alzheimer’s Disease |
Disclosure: Dr. Unger has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Cytomegalovirus (CMV) Primoinfection in a patient with Multiple Sclerosis treated with Alemtuzumab |
Disclosure: Dr. Aguirre Hernandez has nothing to disclose.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Rapidly progressive dementia with seizures due to venous hypertension from arteriovenous hemodialysis graft |
Disclosure: Dr. Mazzola has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Clinical Factors Predicting Cognitive Errors in The Misdiagnosis of Amyotrophic Lateral Sclerosis (ALS) |
Disclosure: Dr. Gummi has nothing to disclose.
|
Epilepsy: General Medical Issues, PNES, and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Acute Seizure Incidence in Ischemic Stroke Patients Treated with Mechanical retrieval therapy: A Single Center Study |
Disclosure: Dr. Morris has nothing to disclose.
|
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Migraine and the Prevalence of Metabolic Syndrome among Women |
Disclosure: Dr. Rist has received personal compensation in an editorial capacity for Stroke - a journal of the American Heart Association.
|
Dystonia and Botulinum Toxin Therapy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Botulinum Toxin for the treatment of muscle spasms associated with Stiff Person Syndrome |
Disclosure: Dr. Moukheiber has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Neuroinvasive West Nile Virus: a Case Series in Nebraska |
Disclosure: Dr. Purbaugh has nothing to disclose.
|
Aging and Dementia: Neuropsychology and Clinical Studies II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | The Role of Population Receptive Fields' Size in Understanding Complex Visual Dysfunctions: Posterior Cortical Atrophy Model |
Disclosure: Dr. De Best has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Changes in the immune cell profile in fingolimod-treated patients with relapsing multiple sclerosis: primary analysis of the FLUENT study |
Disclosure: Dr. Mao-Draayer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Accorda, Biogen, Bayer Pharmaceutical, Celgene, Teva, Genentech, Sanofi-Genzyme, Novartis, Chugai and EMD Serono. Dr. Mao-Draayer has received research support from NIH NIAID Autoimmune Center of Excellence, Sanofi-Genzyme, Novartis and Chugai.
|
Unusual Stroke Etiologies, Presentations and Treatments | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Recurrent Stroke in Giant Cell Arteritis Despite Immunotherapy |
Disclosure: Dr. Cox has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Facial Onset Sensory-Motor Neuronopathy: A Series of Two Cases Illustrating a Disease Spectrum |
Disclosure: Dr. Yasin has nothing to disclose.
|
Epilepsy: General Medical Issues, PNES, and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Postencephalitic Epilepsy and Acute Symptomatic Seizures, in Infectious, Undetermined Etiology and Autoimmune Encephalitis |
Disclosure: Dr. Marone has nothing to disclose.
|
Child Neurology: Movement Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Genetic testing of >1300 patients with cerebral palsy reveals an etiology in one-third of cases, underscoring the need for broad genetic testing and a significant recurrence risk for families. |
Disclosure: Dr. Millan Zamora has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GeneDx.
|
Other Hyperkinetic Movement Disorders and Tremor | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Tremor in the Degenerative Cerebellum: Towards the Understanding of Brain Circuitry for Tremor |
Disclosure: Dr. Kuo has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | West Nile Virus Encephalitis Associated with Intraventricular Diffusion Restriction |
Disclosure: Dr. Shetty has nothing to disclose.
|
Aging and Dementia: Neuropsychology and Clinical Studies II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Quantification of Real-World Life Space from Instrumented Vehicles in Drivers with Cognitive Aging |
Disclosure: Dr. Merickel has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Multiple sclerosis treatment strategy after natalizumab-associated progressive multifocal leukoencephalopathy |
Disclosure: Dr. Waheed has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Outcomes of Mechanical Retrieval Therapy in Basilar Artery Occlusions: A Single Center Study |
Disclosure: Dr. Hawkins has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Frequency, Symptomology, and Course of HIV-Associated ALS: Case Series and Review |
Disclosure: Dr. Satin has nothing to disclose.
|
Epilepsy: General Medical Issues, PNES, and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Epilepsia Partialis Continua Secondary to Diabetic Ketoacidosis |
Disclosure: Dr. Van Orman has nothing to disclose.
|
Child Neurology: Movement Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Evalualuation of Tremor in Childhood Electrophysiologically Influences Prognosis and Outcome |
Disclosure: Dr. Lavenstein has nothing to disclose.
|
Other Hyperkinetic Movement Disorders and Tremor | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Cerebellar Structure in Patients with Parkinson’s Disease and Essential Tremor |
Disclosure: Dr. Lopez has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | A Case of Presumed Post-Transplant West Nile Virus Encephalitis without CSF Pleocytosis or IgM Positivity |
Disclosure: Dr. Shetty has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Increased Multiple Sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate |
Disclosure: Dr. Delgado has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Outcomes of Acute Basilar Occlusion Ischemic Strokes with Advent of Modern Thrombectomy Devices, a New York State Experience |
Disclosure: Dr. Vanguru has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Primary Lateral Sclerosis (PLS) vs. Hereditary Spastic Paraperesis (HSP) in Presenilin-1 (PSEN1) related Dominant Dementia |
Disclosure: Dr. Ahmadi Jazi has nothing to disclose.
|
Epilepsy: General Medical Issues, PNES, and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Two Cases of Provoked Seizure Associated With Kratom Ingestion |
Disclosure: Dr. Burke has nothing to disclose.
|
Child Neurology: Movement Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Alice in Wonderland Syndrome: Case Series and Analysis |
Disclosure: Dr. Fine has nothing to disclose.
|
Other Hyperkinetic Movement Disorders and Tremor | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | The importance of intra-operative assessment in VIM DBS for Tremor: Insights from 145 procedures |
Disclosure: Dr. Mahajan has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Cerebrovascular manifestations of herpes simplex virus infection of the central nervous system: a systematic review |
Disclosure: Dr. Sellner has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | The Marburg Multiple Sclerosis - Cohort — Loss of MEDA under two standard treatment sequences |
Disclosure: Dr. Jurs has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Thermoregulatory Dysfunction in a Patient with Locked-in Syndrome Due to Bilateral Ventral Pontine Infarction |
Disclosure: Dr. Jordan has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Multielectrode array analysis of human iPSC-motor neuron maturation following co-culture with iPSC- spinal cord astrocytes |
Disclosure: Dr. Taga has nothing to disclose.
|
Epilepsy: General Medical Issues, PNES, and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Medically Refractory Epilepsy Associated with Celiac Disease |
Disclosure: Dr. Postelnik has nothing to disclose.
|
Child Neurology: Movement Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Neuropsychological Assessment In Patients With Alternating Hemiplegia Of Childhood (AHC) |
Disclosure: Dr. Fernandes has nothing to disclose.
|
Other Hyperkinetic Movement Disorders and Tremor | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Risk Factors Causing Extended Hospitalizations due to Altered Arousal and Speech Dysfunction Following Deep Brain Stimulation for Essential Tremor |
Disclosure: Dr. Anderson has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Super Refractory Status Epilepticus Secondary to La Crosse Virus Encephalitis: A Case Report |
Disclosure: Dr. Mohl has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Immunosuppresion following alemtuzumab in relapsing-remitting multiple sclerosis patients previously treated with fingolimod |
Disclosure: Dr. Cabrera Maqueda has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Outcome in Acute Basilar Artery Occlusion Based on Time and Severity at Presentation: A Retrospective Review |
Disclosure: Dr. Suriya has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Patient-Reported Outcomes Measures in Children with Spinal Muscular Atrophy |
Disclosure: Dr. Risson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Pharma AG, Basel, Switzerland.
|
Epilepsy: General Medical Issues, PNES, and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Profile and Outcome of Psychogenic Nonepileptic Seizures Patients undergoing Video-EEG Monitoring |
Disclosure: Dr. Wolfe has nothing to disclose.
|
Child Neurology: Movement Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Insights into Alternating Hemiplegia of Childhood from EEG Monitoring during an Episode, and Successful Prophylaxis with Levetiracetam |
Disclosure: Dr. Mirzoev has nothing to disclose.
|
Other Hyperkinetic Movement Disorders and Tremor | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Distinguishing tremor components in Essential Tremor: a digital spirography study |
Disclosure: Dr. Osterholt has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | Unusual movement disorders and atypical MRI findings in patients with West Nile Encephalitis: A case series of two patients with evidence of clinical and imaging resolution with IVIG |
Disclosure: Dr. Sheikh has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | PML Risk Perception in Patients Initiating Natalizumab for Multiple Sclerosis |
Disclosure: Dr. Berkovich has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Avanir, Bayer, Biogen, Novartis, Questcor, Sanofi, and Teva. Dr. Berkovich has received research support from Acorda, Avanir, Bayer, Biogen, Novartis, Questcor, Sanofi, and Teva.
|
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | Association of Functional Outcome in Basilar Artery Occlusion in Relation to Baseline Comorbidities: A Retrospective Review |
Disclosure: Dr. Bzdyra has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | Co-existing riboflavin transporter deficiency (RTD) type 2 and muscle AMP deaminase deficiency in two long-term RTD survivors: report of a family |
Disclosure: Dr. Zhang has nothing to disclose.
|
Epilepsy: General Medical Issues, PNES, and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | An Institutional Experience on Semiology of Psychogenic Nonepileptic Seizures |
Disclosure: Dr. Fahimi has nothing to disclose.
|
Child Neurology: Movement Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | A Very Rare Cause of a Common Tremor |
Disclosure: Dr. Kabbani has nothing to disclose.
|
Other Hyperkinetic Movement Disorders and Tremor | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | Cortical hyperexcitability in sialidosis type 1 |
Disclosure: Dr. Vial has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Elsberg Syndrome, The Often Missed Other Cauda Equina |
Disclosure: Dr. Yogendran has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Temporal profile of lymphocytes following treatment with cladribine tablets in patients switching from lymphocyte depleting or sequestering disease modifying drugs (DMDs) |
Disclosure: Dr. Hodgkinson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Sanofi Genzyme, Novartis.
|
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Interrater Agreement for Measurements of Vertebral Artery Origin Stenosis |
Disclosure: Dr. Bell has nothing to disclose.
|
Motor Neuron Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Effect of Radicava on Uric Acid Levels: Preliminary Results |
Disclosure: Dr. Heiman-Patterson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cytokinetics, Mitsubishi Tanabe, PTC Therapeutics.
|
Epilepsy: General Medical Issues, PNES, and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Serum Levels of Inflammasome Complex Factors are Suppressed in Focal Epilepsy Patients |
Disclosure: Dr. Yavuz has nothing to disclose.
|
Child Neurology: Movement Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | KMT2B early childhood onset dystonia presenting as failure to thrive |
Disclosure: Dr. Ng has nothing to disclose.
|
Other Hyperkinetic Movement Disorders and Tremor | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Hyperkinetic Movement Disorders Associated With Immunosuppressant And Cefepime Use In Inpatients |
Disclosure: Dr. Couto has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | A 59-year-old Immunocompetent Man with Rapid Onset of Truncal Ataxia: A Case of Acute Cerebellitis Secondary to Varicella Zoster Virus. |
Disclosure: Dr. Cross has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Predicting Natalizumab Discontinuation due to Breakthrough Disease in Multiple Sclerosis Patients |
Disclosure: Dr. Conway has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Arena pharmaceuticals. Dr. Conway has received personal compensation in an editorial capacity for Neurotherapeutics. Dr. Conway has received research support from Novartis Pharmaceuticals.
|
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Comparison Between Medical Therapy And Endovascular Treatment Of Extracranial Atherosclerotic Vertebral Artery Disease: A Systematic Review |
Disclosure: Dr. Daniel has nothing to disclose.
|
Neurophysiology in Neuromuscular Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Hybrid Recording System of Electromyography and Ultrasound in Neuromuscular Disorder |
Disclosure: Dr. Sekiguchi has nothing to disclose.
|
Child Neurology: Neuroinflammatory Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Cortical Abnormalities and Cognitive Impairment in Pediatric MS Patients |
Disclosure: Dr. De Meo has nothing to disclose.
|
Other Hyperkinetic Movement Disorders and Tremor | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Effects of Concomitant Medication Use on Tardive Dyskinesia Outcomes in Long-Term Valbenazine Trials |
Disclosure: Dr. Comella has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda Therapeutics, Allergan, Inc; Lundbeck Ltd.; Merz Pharmaceuticals;Acadia Pharmaceuticals; Ipsen Pharmaceuticals, Jazz Pharmaceuticals, Neurocrine Biosciences Inc., Revance Therapeutic, Sunovion., AEON Biopharma. She receives royalties from Cambridge, Wolters Kluwer. . Dr. Comella has received research support from Acorda, Revance, Merz, Eisai, Jazz Pharmacuetical.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Oculomeningoencephalomyeloradiculitis: A case of fulminant varicella zoster infection in the setting of systemic lupus erythematosus |
Disclosure: Dr. Perrone has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Skin Warts during Fingolimod Treatment in Patients with Multiple Sclerosis |
Disclosure: Dr. Yamout has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Genpharm, Genzyme, Merck-Serono, Novartis. Dr. Yamout has received research support from Bayer, Biogen, Merck-Serono, Novartis, Pfizer.
|
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Prevalence of Atherosclerotic Vertebrobasilar Disease in patients with Ischemic Stroke in an Argentinian cohort of patients |
Disclosure: Dr. Bandeo has nothing to disclose.
|
Neurophysiology in Neuromuscular Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Safety of Needle Electromyography in Critically Ill Intensive Care Unit (ICU) Patients |
Disclosure: Dr. Nagarajan has nothing to disclose.
|
Epilepsy: General Medical Issues, PNES, and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Spanish Epilepsy Education Available on the Web |
Disclosure: Dr. Duron has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Epilepsy Foundation of Greater Los Angeles.
|
Child Neurology: Neuroinflammatory Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Imaging analysis differentiates vascular versus inflammatory myelopathies in children |
Disclosure: Dr. Garcia-Dominguez has nothing to disclose.
|
Other Hyperkinetic Movement Disorders and Tremor | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | RECLAIM-DCP: A Randomized, Double-Blind, Placebo-Controlled Study of Deutetrabenazine for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents |
Disclosure: Dr. Claassen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Neuroscience, Lundbeck, Acadia, AbbVie. Dr. Claassen has received research support from NIH/NINDS, Michael J. Fox Foundation, Huntington Disease Society of America, Vaccinex, AbbVie, Auspex Pharmaceuticals.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | A Novel Case of Herpes Simplex Encephalitis Complicated by Cerebral Venous Thrombosis |
Disclosure: Dr. Eibling has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with TrueLearn .
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Limited Effects of Interferon ß-1a in an IgG-driven Model of Multiple Sclerosis Pathology |
Disclosure: Dr. Bennett has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Viela Bio, Genentech, Alexion, Roche, Chugai, Frequency Therapeutics, Clene Neuroscience, and Reistone. Dr. Bennett has received royalty, license fees, or contractual rights payments from Pure Biologics. Dr. Bennett has received research support from Mallinckrodt, and EMD Serono.
|
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Second Generation Drug-Eluting Stents for Endovascular Treatment of Ostial Vertebral Artery Stenosis: A Single-Center Experience |
Disclosure: Dr. Mendez Ruiz has nothing to disclose.
|
Child Neurology: Neuroinflammatory Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Autoimmune encephalitis associated with N-type voltage-gated calcium channels in children: a case series |
Disclosure: Dr. Kornitzer has nothing to disclose.
|
Other Hyperkinetic Movement Disorders and Tremor | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Diagnosis and Treatment Experiences in a Real-World Sample of Tourette Syndrome and Tic Disorder Sufferers |
Disclosure: Dr. Malaty has received research support from Abbvie, Auspex, Biogen, Biotie, Impax, Intrepid, Lundbeck, Nuvelution, Pfizer, and Revance.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | Neuroinvasive Spectrum of West Nile Virus. |
Disclosure: Dr. Srinivas has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | Autoimmune Hemolytic Anemia after Treatment with Fingolimod: A Case Report |
Disclosure: Dr. Husain has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | : Vertebral artery origin stenosis: systematic review of randomized clinical trials |
Disclosure: Dr. Ezepue has nothing to disclose.
|
Neurophysiology in Neuromuscular Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | The Neurophysiology of Oxaliplatin Effects on Peripheral Nerve |
Disclosure: Dr. Stecker has received royalty, license fees, or contractual rights payments from UPTODate.
|
Child Neurology: Neuroinflammatory Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | Autoimmune Glial Fibrillary Acidic Protein (GFAP) Astrocytopathy Following Herpes Simplex Encephalitis (HSE) in a pediatric patient |
Disclosure: Dr. Handoko has nothing to disclose.
|
Other Hyperkinetic Movement Disorders and Tremor | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | Self-Reported Substance Use in a Real-World Sample of Subjects with Tourette Syndrome and Other Tic Disorder. |
Disclosure: Dr. Deeb has received research support from Tools4Patients.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Post-operative HSV-2 Encephalitis Following Temporal Lobe Resection for Glioblastoma Multiforme |
Disclosure: Dr. Mingbunjerdsuk has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Longitudinal analysis of Peripheral Blood Mononuclear Cells in Lymphopenic and Non-lymphopenic Relapsing-Remitting Multiple Sclerosis (RRMS) patients treated with Dimethyl Fumarate |
Disclosure: Dr. Nakhaei-Nejad has nothing to disclose.
|
Stroke Genetics and Epidemiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Concerning Temporal Trends in Transient Ischemic Attack Hospitalization |
Disclosure: Dr. Sahawneh has nothing to disclose.
|
Neurophysiology in Neuromuscular Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Increased Incidence of Martin Gruber Anastomosis in Individuals with Ulnar Neuropathy |
Disclosure: Dr. Gandhy has nothing to disclose.
|
Child Neurology: Neuroinflammatory Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Unilateral Primary CNS Vasculitis in a Child Associated with Increased ICP and Treated with Maximal Medical Therapy and Decompressive Hemicraniectomy |
Disclosure: Dr. Wang has nothing to disclose.
|
Other Hyperkinetic Movement Disorders and Tremor | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Physical activity, sleep and tic severity in children |
Disclosure: Dr. Pringsheim has nothing to disclose.
|
Neurovirology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 040 | Acute Myositis in Three Adult Men with Rapid Resolution |
Disclosure: Dr. Danielson has nothing to disclose.
|
MS Therapeutics: MOA and Safety | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 040 | Stability of JC Virus Index over Time – a Five Year Retrospective Study. |
Disclosure: Dr. Gaughan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche, Novartis, Abbvie, Biogen. Dr. Gaughan has received research support from Roche via Newman Fellowship, University College Dublin.
|
Stroke Genetics and Epidemiology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 040 | Healthcare Utilization Prior to Fatal Stroke Admission: Nationally Representative Data |
Disclosure: |